Mostrar el registro sencillo del ítem

Preclinical Research of Dihydromyricetin for Brain Aging and Neurodegenerative Diseases

dc.rights.licensehttp://creativecommons.org/licenses/by/4.0es_MX
dc.creatorHILDA MARTINEZ CORIAes_MX
dc.creatorXOCHIQUETZALLI MENDOZA ROJASes_MX
dc.creatorISABEL ARRIETA CRUZes_MX
dc.creatorHECTOR EDUARDO LOPEZ VALDESes_MX
dc.date2019
dc.date.accessioned2021-08-24T18:46:14Z
dc.date.available2021-08-24T18:46:14Z
dc.identifier.urihttp://repositorio.inger.gob.mx/jspui/handle/20.500.12100/17230
dc.descriptionBrain aging and neurodegenerative diseases share the hallmarks of slow and progressive loss of neuronal cells. Flavonoids, a subgroup of polyphenols, are broadly present in food and beverage and numerous studies have suggested that it could be useful for preventing or treating neurodegenerative diseases in humans. Dihydromyricetin (DHM) is one of the main flavonoids of some Asian medicinal plants that are used to treat diverse illness. The effects of DHM have been studied in different in vitro systems of oxidative damage and neuroinflammation, as well as in animal models of several neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Here we analyzed the most important effects of DHM, including its antioxidant, anti-inflammatory, and neuroprotective effects, as well as its ability to restore GABA neurotransmission and improve motor and cognitive behavior. We propose new areas of research that might contribute to a better understanding of the mechanism of action of this flavonoid, which could help develop a new therapy for aging and age-related brain diseases.es_MX
dc.formatAdobe PDFes_MX
dc.languageenges_MX
dc.publisherFrontiers Mediaes_MX
dc.relationhttps://www.frontiersin.org/articles/10.3389/fphar.2019.01334/fulles_MX
dc.relation.requiresSies_MX
dc.rightsAcceso Abiertoes_MX
dc.sourceFrontiers in Pharmacology (1663-9812) Vol. 10 (2019)es_MX
dc.subjectMEDICINA Y CIENCIAS DE LA SALUDes_MX
dc.subjectCiencias médicases_MX
dc.subjectCiencias clínicases_MX
dc.subjectGeriatríaes_MX
dc.subjectEnfermedades del sistema nerviosoes_MX
dc.subjectEnfermedades neurodegenerativases_MX
dc.subjectEnfermedades de los ganglios basaleses_MX
dc.subjectEnfermedad de Huntingtones_MX
dc.subjectTrastornos parkinsonianoses_MX
dc.subjectEnfermedad de Parkinsones_MX
dc.subjectDemenciaes_MX
dc.subjectEnfermedad de Alzheimeres_MX
dc.subjectEnvejecimientoes_MX
dc.subjectGeriatricses_MX
dc.subjectNervous system diseaseses_MX
dc.subjectNeurodegenerative diseaseses_MX
dc.subjectBasal ganglia diseaseses_MX
dc.subjectHuntington diseasees_MX
dc.subjectParkinsonian disorderses_MX
dc.subjectParkinson diseasees_MX
dc.subjectDementiaes_MX
dc.subjectAlzheimer diseasees_MX
dc.subjectAginges_MX
dc.titlePreclinical Research of Dihydromyricetin for Brain Aging and Neurodegenerative Diseaseses_MX
dc.typeArtículoes_MX
dc.audienceResearcherses_MX
dc.creator.idMACH660202MDFRRL03es_MX
dc.creator.idMERX950505MDFNJC03es_MX
dc.creator.idAICI730724MDFRRS06es_MX
dc.creator.idLOVH620512HDFPLC00es_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX


Ficheros en el ítem

Thumbnail
Nombre:
Frontiers in Pharmacology ...
Tamaño:
843.7Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem